Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2016 07:45 ET | Source: Calithera Biosciences, Inc.

Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
September 07, 2016 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the discovering and developing novel...
August 31, 2016 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present at Two Healthcare Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
August 10, 2016 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Appoints Suzy Jones to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel...
August 09, 2016 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights

Two novel agents that modulate tumor and immune cell metabolism in clinical developmentCalithera to host conference call today at 4:30pm ET SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE...
August 04, 2016 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
August 02, 2016 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
July 25, 2016 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint

SOUTH SAN FRANCISCO, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
June 06, 2016 07:30 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting

Future development to focus on renal cell carcinoma and triple negative breast cancerCalithera to host investor webcast on June 6, 2015 at 6:30 p.m. CT SOUTH SAN FRANCISCO, Calif., June 06, 2016 ...
May 10, 2016 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2016 Financial Results and Recent Highlights

- CB-839 Phase 1b Clinical Data to be Presented at ASCO 2016- Key clinical leadership expansion- Calithera to Host Conference Call Today at 4:30pm Eastern TimeSOUTH SAN FRANCISCO, Calif.,...